Seeking to dampen high prices for new drugs, CVS Caremark plans to allow its clients — such as health plans and employers — to exclude from their formularies any new medicine that has a higher price than a specific threshold for determining value.

Specifically, the pharmacy benefit manager set a threshold of $100,000 per QALY, or quality-of-life years, a benchmark that measures both the quantity and quality of life generated by providing a treatment or some other health care intervention. In the U.S., anywhere from $50,000 to $150,000 is used for gauging value, although $100,000 is commonly used as a threshold.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I guess no one is paying attention again. This is a corporate PR or advertising campaign. It is highly obvious that these corporations have corrupted science. They will merely deceive the public by appearing to be “Cost Saving.” Thanks to the lack of critical thinking occurring here and on most other sites, they will peddle this propaganda. Doing a Cost benefit analysis, sounds a lot like Healthcare rationing to me. Anything is better than looking at the root of the problem here. We need to demand fact based prescription drugs. The government should disband these monopolies, it is to late to fix this. Watch how every medical journalist educated by Pharam will sell this idea as “innovative.”

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy